Literature DB >> 15776407

Homology modeling and molecular dynamics simulations of the mu opioid receptor in a membrane-aqueous system.

Yan Zhang1, Yuk Y Sham, Ramkumar Rajamani, Jiali Gao, Philip S Portoghese.   

Abstract

Three types of opioid receptors-mu, delta, and kappa-belong to the rhodopsin subfamily in the G protein-coupled receptor superfamily. With the recent characterization of the high-resolution X-ray crystal structure of bovine rhodopsin, considerable attention has been focused on molecular modeling of these transmembrane proteins. In this study, a homology model of the mu opioid receptor was constructed based on the X-ray crystal structure of bovine rhodopsin. A phospholipid bilayer was built around the receptor, and two water layers were placed on both surfaces of the lipid bilayer. Molecular-dynamics simulations were carried out by using CHARMM for the entire system, which consisted of 316 amino acid residues, 92 phospholipid molecules, 8327 water molecules, and 11 chloride counter ions-40 931 atoms altogether. The whole system was equilibrated for 250 ps followed by another 2 ns dynamic simulation. The opioid ligand naltrexone was docked into the optimized model, and the critical amino acid residues for binding were identified. The mu opioid receptor homology model optimized in a complete membrane-aqueous system should provide a good starting point for further characterization of the binding modes for opioid ligands. Furthermore, the method developed herein will be applicable to molecular model building to other opioid receptors as well as other GPCRs.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15776407     DOI: 10.1002/cbic.200400207

Source DB:  PubMed          Journal:  Chembiochem        ISSN: 1439-4227            Impact factor:   3.164


  14 in total

1.  Exploring the structure of opioid receptors with homology modeling based on single and multiple templates and subsequent docking: a comparative study.

Authors:  Indrani Bera; Aparna Laskar; Nanda Ghoshal
Journal:  J Mol Model       Date:  2010-07-27       Impact factor: 1.810

2.  Ligand specificity of odorant receptors.

Authors:  Kamil Khafizov; Claudio Anselmi; Anna Menini; Paolo Carloni
Journal:  J Mol Model       Date:  2006-11-21       Impact factor: 1.810

3.  Probing a model of a GPCR/ligand complex in an explicit membrane environment: the human cholecystokinin-1 receptor.

Authors:  Jérôme Hénin; Bernard Maigret; Mounir Tarek; Chantal Escrieut; Daniel Fourmy; Christophe Chipot
Journal:  Biophys J       Date:  2005-12-02       Impact factor: 4.033

4.  Mutations in the amino terminus of herpes simplex virus type 1 gL can reduce cell-cell fusion without affecting gH/gL trafficking.

Authors:  Wenbo Zhou; Feng Chen; Yuri Klyachkin; Yuk Y Sham; Robert J Geraghty
Journal:  J Virol       Date:  2013-10-23       Impact factor: 5.103

5.  Consensus 3D model of μ-opioid receptor ligand efficacy based on a quantitative Conformationally Sampled Pharmacophore.

Authors:  Jihyun Shim; Andrew Coop; Alexander D MacKerell
Journal:  J Phys Chem B       Date:  2011-05-12       Impact factor: 2.991

6.  Inhibition of Inflammatory and Neuropathic Pain by Targeting a Mu Opioid Receptor/Chemokine Receptor5 Heteromer (MOR-CCR5).

Authors:  Eyup Akgün; Muhammad I Javed; Mary M Lunzer; Michael D Powers; Yuk Y Sham; Yoshikazu Watanabe; Philip S Portoghese
Journal:  J Med Chem       Date:  2015-10-20       Impact factor: 7.446

7.  Insights into the Allosteric Mechanism of Setmelanotide (RM-493) as a Potent and First-in-Class Melanocortin-4 Receptor (MC4R) Agonist To Treat Rare Genetic Disorders of Obesity through an in Silico Approach.

Authors:  Bethany A Falls; Yan Zhang
Journal:  ACS Chem Neurosci       Date:  2018-08-13       Impact factor: 4.418

8.  Insights into subtype selectivity of opioid agonists by ligand-based and structure-based methods.

Authors:  Jianxin Cheng; Guixia Liu; Jing Zhang; Zhejun Xu; Yun Tang
Journal:  J Mol Model       Date:  2010-05-25       Impact factor: 1.810

9.  Comparative docking study of anibamine as the first natural product CCR5 antagonist in CCR5 homology models.

Authors:  Guo Li; Kendra M Haney; Glen E Kellogg; Yan Zhang
Journal:  J Chem Inf Model       Date:  2009-01       Impact factor: 4.956

10.  Design, synthesis, and biological evaluation of 6alpha- and 6beta-N-heterocyclic substituted naltrexamine derivatives as mu opioid receptor selective antagonists.

Authors:  Guo Li; Lindsey C Aschenbach; Jianyang Chen; Michael P Cassidy; David L Stevens; Bichoy H Gabra; Dana E Selley; William L Dewey; Richard B Westkaemper; Yan Zhang
Journal:  J Med Chem       Date:  2009-03-12       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.